KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Free Cash Flow (2018 - 2025)

Moderna (MRNA) has disclosed Free Cash Flow for 8 consecutive years, with $891.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 194.06% to $891.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 billion through Dec 2025, up 49.08% year-over-year, with the annual reading at -$2.1 billion for FY2025, 49.08% up from the prior year.
  • Free Cash Flow for Q4 2025 was $891.0 million at Moderna, up from -$953.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was $4.0 billion in Q2 2021, with the low at -$2.0 billion in Q3 2024.
  • Average Free Cash Flow over 5 years is $436.1 million, with a median of $148.0 million recorded in 2022.
  • The sharpest move saw Free Cash Flow skyrocketed 9446.51% in 2021, then crashed 19914.29% in 2023.
  • Over 5 years, Free Cash Flow stood at $3.3 billion in 2021, then plummeted by 51.91% to $1.6 billion in 2022, then plummeted by 59.24% to $640.0 million in 2023, then plummeted by 52.66% to $303.0 million in 2024, then soared by 194.06% to $891.0 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $891.0 million, -$953.0 million, and -$916.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.